Respiratory syncytial virus infections - recent developments providing promising new tools for disease prevention.
作者信息
Broberg Eeva K, Nohynek Hanna
机构信息
European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Finnish institute for health and welfare, Helsinki, Finland.
出版信息
Euro Surveill. 2023 Dec;28(49). doi: 10.2807/1560-7917.ES.2023.28.49.2300686.
Abstract
摘要
相似文献
1
Respiratory syncytial virus infections - recent developments providing promising new tools for disease prevention.
Euro Surveill. 2023 Dec;28(49). doi: 10.2807/1560-7917.ES.2023.28.49.2300686.
2
Molecular Modeling Predicts Novel Antibody Escape Mutations in the Respiratory Syncytial Virus Fusion Glycoprotein.
J Virol. 2022 Jul 13;96(13):e0035322. doi: 10.1128/jvi.00353-22. Epub 2022 Jun 9.
3
Target capture sequencing reveals a monoclonal outbreak of respiratory syncytial virus B infections among adult hematologic patients.
Antimicrob Resist Infect Control. 2022 Jun 21;11(1):88. doi: 10.1186/s13756-022-01120-z.
4
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.
Lancet Infect Dis. 2023 Jan;23(1):e2-e21. doi: 10.1016/S1473-3099(22)00291-2. Epub 2022 Aug 8.
5
Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection.
Semin Perinatol. 1998 Feb;22(1):87-95. doi: 10.1016/s0146-0005(98)80010-4.
6
Palivizumab in the prophylaxis of respiratory syncytial virus infection.
Expert Rev Anti Infect Ther. 2005 Oct;3(5):719-26. doi: 10.1586/14787210.3.5.719.
7
Genomic characterisation of respiratory syncytial virus: a novel system for whole genome sequencing and full-length G and F gene sequences.
Euro Surveill. 2023 Dec;28(49). doi: 10.2807/1560-7917.ES.2023.28.49.2300637.
8
Respiratory syncytial virus infection in the modern era.
Curr Opin Infect Dis. 2023 Jun 1;36(3):155-163. doi: 10.1097/QCO.0000000000000917. Epub 2023 Mar 20.
9
Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
JAMA Netw Open. 2023 Feb 1;6(2):e230023. doi: 10.1001/jamanetworkopen.2023.0023.
10
Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood.
J Pediatr (Rio J). 2023 Mar-Apr;99 Suppl 1(Suppl 1):S4-S11. doi: 10.1016/j.jped.2022.10.004. Epub 2022 Nov 17.
引用本文的文献
1
Addressing the Underestimated Burden of RSV in Older Adults in Europe: Epidemiology, Surveillance Gaps, and Public Health Implications.
Vaccines (Basel). 2025 May 12;13(5):510. doi: 10.3390/vaccines13050510.
2
Global meta-analysis of short-term associations between ambient temperature and pathogen-specific respiratory infections, 2004 to 2023.
Euro Surveill. 2025 Mar;30(11). doi: 10.2807/1560-7917.ES.2025.30.11.2400375.
3
Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.
Influenza Other Respir Viruses. 2024 May;18(5):e13294. doi: 10.1111/irv.13294.
4
RSV immunisation in infants: weighing the options.
Lancet Reg Health Eur. 2024 Feb 8;38:100867. doi: 10.1016/j.lanepe.2024.100867. eCollection 2024 Mar.
5
Respiratory Syncytial Virus (RSV) and Intention to Recommend RSV Vaccination: A Cross-Sectional Survey of Cardiologists and Cardiac Nurses in Southern Italy.
Infect Dis Rep. 2024 Feb 15;16(1):128-141. doi: 10.3390/idr16010010.
6
Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg.
Euro Surveill. 2024 Jan;29(4). doi: 10.2807/1560-7917.ES.2024.29.4.2400033.
本文引用的文献
1
Genomic characterisation of respiratory syncytial virus: a novel system for whole genome sequencing and full-length G and F gene sequences.
Euro Surveill. 2023 Dec;28(49). doi: 10.2807/1560-7917.ES.2023.28.49.2300637.
2
Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023.
Euro Surveill. 2023 Dec;28(49). doi: 10.2807/1560-7917.ES.2023.28.49.2300606.
3
Universal infant immunisation against respiratory syncytial virus and European inequalities: the pandemics lesson has not been learnt.
Lancet Reg Health Eur. 2023 Oct 11;34:100753. doi: 10.1016/j.lanepe.2023.100753. eCollection 2023 Nov.
4
Estimation of the Number of Respiratory Syncytial Virus-Associated Hospitalizations in Adults in the European Union.
J Infect Dis. 2023 Nov 28;228(11):1539-1548. doi: 10.1093/infdis/jiad189.
5
The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis.
Front Pediatr. 2023 Apr 4;11:1132740. doi: 10.3389/fped.2023.1132740. eCollection 2023.
6
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.
N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5.
7
Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries.
Vaccine. 2023 Feb 24;41(9):1623-1631. doi: 10.1016/j.vaccine.2023.01.058. Epub 2023 Feb 1.
8
Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study.
Value Health. 2023 Apr;26(4):508-518. doi: 10.1016/j.jval.2022.11.014. Epub 2022 Nov 26.
9
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study.
Lancet Respir Med. 2023 Apr;11(4):341-353. doi: 10.1016/S2213-2600(22)00414-3. Epub 2022 Nov 10.
10
Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study.
BMC Infect Dis. 2022 Sep 29;22(1):759. doi: 10.1186/s12879-022-07745-0.
Zotero 插件